Brief: CSPC Pharmaceutical Says FY Net Loss Attributable For CSPC Innovation Pharmaceutical Of RMB241.1 MLN
16/03/2026 19:00
March 17 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK: FY NET LOSS ATTRIBUTABLE FOR CSPC INNOVATION PHARMACEUTICAL RMB241.1 MILLION FY OPERATING REVENUE FOR CSPC INNOVATION PHARMACEUTICAL RMB 2.16 BILLION Further company coverage: 1093.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines